{"metadata": {"organization_names": [], "person_names_verified": ["thomas murphy", "charan j. sandhu", "joshua m. marks", "michael p. duffy"], "organization_names_verified": ["weil, gotshal & manges", "bvl\u2019s technology", "bvl technology", "ben venue laboratories", "lantheus medical imaging, inc.", "bvl for manufacturing, development"], "vars": {}, "entities_rejected": [], "person_names": ["neurolite ligand"], "agreement_id": "84915ce39ec1fa84b7cf521dcfb1cd3b041b799143ebf5536449302454307738", "topics": [], "terms": ["**   %   **", "** (**", "** (****", "** Dollars ($****", "** days in advance or ****", "** dollars ($****", "** price adjustments will be effective as of ****", "**), BVL agrees to reimburse Customer up to a maximum of $****", "****", "**** (****", "**** (at ****", "**** DOLLARS ($****", "**** as applicable, or the insurance levels identified in Section 8.4 or elsewhere, in no event shall BVL\u2019s liability to Customer for in-process loss of API or Customer-supplied Composition be in excess of $**", "**** calendar days of receipt of the complete Batch Records relating to such Batch. If no acceptance or rejection in writing is received by BVL within ****", "**** days and not more than **", "**** days prior to the date of manufacture, BVL will notify Customer of said date of manufacture. The date of manufacture shall not be more than ****", "**** for the following **", "**** maximum as described above as shown by Customer\u2019s written records. The monetary values of all Customer-supplied Composition and API must be disclosed by Customer to BVL in writing prior to production in the questionnaire provided by BVL to Customer. The Customer is responsible for notifying BVL in writing of any changes in the value of the Customer-supplied Composition and API supplied to BVL, and BVL shall not be liable for any increase in the cost of the foregoing if Customer fails to provided the abovementioned notice or timely updates thereto. Notwithstanding the foregoing, or any declared value of API costs in excess of $****", "**** of each ****", "**** percent (****", "**ATTACHMENTS**", "**Attachment \u201cA\u201d**", "**Attachment \u201cB\u201d**", "**Attachment \u201cC\u201d**", "**Attachment \u201cD\u201d**", "**Attachment \u201cE\u201d**", "**Attachment \u201cF\u201d**", "**Attachment \u201cG\u201d**", "**BVL CAP ON LIABILITY**", "**CONFIDENTIAL TREATMENT REQUESTED**", "**CONFIDENTIAL**", "**ELECTION OF REMEDIES**", "**INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH \u201c****\u201d", "**INTEGRAL PROVISIONS.**", "**Manufacturing and Service Contract For Commercial and Developmental Products**", "**Page**", "**Product**", "**SPECIAL DAMAGES**", "**Table of Contents**", "**WITNESSETH:**", "**Year 1**", "**Year 2**", "**Year 3-5**", "**[SEAL]**", "*-*", "*Additional Attachments for Use if \u201cTerritory\u201d for any Product includes the European Union:*", "*Definity*", "*i.e*", "*i.e.*", "*i.e.,*", "*pro*", "*rata*", "\u201c1993 Agreement\u201d", "\u201cA#.6\u201d", "\u201cAgreement\u201d", "\u201cBVL Indemnitees\u201d", "\u201cBVL\u201d and as further defined in Article I) and Lantheus Medical Imaging, Inc., a corporation organized and existing under laws of Delaware, with its principal place of business at 331 Treble Cove Road, [[Address 2: Address]] (hereinafter \u201cCustomer\u201d", "\u201cCommitment Table\u201d", "\u201cEMEA\u201d", "\u201cEffective Date\u201d", "\u201cE\u201d", "\u201cFive-Year Forecast\u201d", "\u201cForce Majeure\u201d", "\u201cInitial Term\u201d", "\u201cObsolete Materials\u201d", "\u201cOther Invention\u201d", "\u201cRolling Forecast\u201d", "\u201cSPECIAL DAMAGES\u201d", "\u201cTPM EHS Assessment Program\u201d"]}}